Skip to main content

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

*June 2022*


  • Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial.
  • Although the 12-month PFS probability was 70.2%, which did not meet the primary end point, the median PFS was 21.3 months suggesting the promising efficacy of this alternative therapy.
  • Our results are indicative of the feasibility of alternating therapy with osimertinib and afatinib.
  • The study treatment is effective even in patients with TP53 mutations or EGFR compound mutations from exploratory cfDNA analysis results

Read more.